Toripalimab with chemo-radiation before surgery for rectal cancer
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial studies whether adding toripalimab (an immunotherapy drug) to standard chemo-radiation before surgery can improve outcomes for people with higher-risk, locally advanced rectal cancer. It is meant for cancers that are mismatch-repair “MSS/pMMR,” and it checks safety plus effectiveness as a first treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 to 75 years old
- Your rectal cancer is confirmed as MSS or pMMR (not another mismatch-repair type)
- Your cancer is stage T3–4 and has at least one “high-risk” feature (CRM+, EMVI+, or lymph nodes on the side)
- You have not had chemotherapy, radiation, immunotherapy, or other anti-cancer treatment before starting this study
- Your blood tests and liver/kidney function are strong enough for treatment (meet the trial’s lab cutoffs)
- You have no certain health conditions like uncontrolled autoimmune disease, hepatitis B/C, or major immunodeficiency
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new approach for people with locally advanced rectal cancer that has high-risk features. It combines short-course radiation with chemotherapy (CapeOX) and the immunotherapy drug toripalimab, with or without another drug called surufatinib, before surgery. The goal is to see if adding these drugs helps shrink the tumor and improve outcomes.
This trial tests whether adding an immunotherapy drug called tislelizumab to standard chemotherapy and radiation can help patients with early-stage rectal cancer (cancer within 3 cm of the opening of the rectum) avoid surgery or improve surgery outcomes. The goal is to see if this combination is safe and effective.
This trial tests a combination of radiation, two immunotherapy drugs (iparomlimab and tuvonralimab), a targeted therapy (regorafenib), and chemotherapy (CAPOX) given before surgery for locally advanced rectal cancer. The goal is to see if this approach can shrink the tumor and improve outcomes for people whose tumors have normal mismatch repair proteins (pMMR/MSS).
This trial studies a treatment given before surgery using toripalimab, with or without celecoxib, for colon or rectal cancer that has MSI-H or dMMR tumor features. It aims to shrink or control the cancer before the operation and compare whether adding celecoxib helps.
This trial compares a new treatment approach—short-course radiation followed by an immunotherapy drug (PD-1 inhibitor) and chemotherapy (FOLFOX)—to the standard long-course chemoradiation for people with a specific type of advanced rectal cancer that is pMMR/MSS. The goal is to see if the shorter treatment works as well or better.
This trial tests combining standard chemoradiation with an immunotherapy drug (toripalimab) before surgery for rectal cancer that has come back in the pelvis. The goal is to see if this approach can help remove the tumor more effectively.
Hear when a new Locally Advanced trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.